It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
CASK-related disorders are genetically defined neurodevelopmental syndromes. There is limited information about the effects of CASK mutations in human neurons. Therefore, we sought to delineate CASK-mutation consequences and neuronal effects using induced pluripotent stem cell-derived neurons from two mutation carriers. One male case with autism spectrum disorder carried a novel splice-site mutation and a female case with intellectual disability carried an intragenic tandem duplication. We show reduction of CASK protein in maturing neurons from the mutation carriers, which leads to significant downregulation of genes involved in presynaptic development and of CASK protein interactors. Furthermore, CASK-deficient neurons showed decreased inhibitory presynapse size as indicated by VGAT staining, which may alter the excitatory–inhibitory (E/I) balance in developing neural circuitries. Using in vivo magnetic resonance spectroscopy quantification of GABA in the male mutation carrier, we further highlight the possibility to validate in vitro cellular data in the brain. Our data show that future pharmacological and clinical studies on targeting presynapses and E/I imbalance could lead to specific treatments for CASK-related disorders.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Karolinska Institutet, and Center for Psychiatry Research, Center of Neurodevelopmental Disorders (KIND), Division of Neuropsychiatry, Department of Women’s and Children’s Health, Region Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Astrid Lindgren Children’s Hospital, Region Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)
2 Karolinska University Hospital, Astrid Lindgren Children’s Hospital, Region Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705); Karolinska Institutet, Department of Women’s and Children’s Health, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
3 Medical Center—University of Freiburg, Faculty of Medicine, University of Freiburg, Department of Psychiatry and Psychotherapy, Freiburg im Breisgau, Germany (GRID:grid.4714.6)
4 Nationwide Children’s Hospital, Department of Radiology, Columbus, USA (GRID:grid.240344.5) (ISNI:0000 0004 0392 3476)
5 Karolinska Institutet, and Center for Psychiatry Research, Center of Neurodevelopmental Disorders (KIND), Division of Neuropsychiatry, Department of Women’s and Children’s Health, Region Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
6 Karolinska Institutet, and Center for Psychiatry Research, Center of Neurodevelopmental Disorders (KIND), Division of Neuropsychiatry, Department of Women’s and Children’s Health, Region Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Astrid Lindgren Children’s Hospital, Region Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705); Heidelberg University, Interdisciplinary Center for Neurosciences, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373)
7 Karolinska Institutet, and Center for Psychiatry Research, Center of Neurodevelopmental Disorders (KIND), Division of Neuropsychiatry, Department of Women’s and Children’s Health, Region Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Gustavus Adolphus College, St. Peter, USA (GRID:grid.256667.6) (ISNI:0000 0001 2192 5385)
8 Karolinska Institutet, Department of Neuroscience, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
9 Karolinska Institutet, Department of Molecular Medicine and Surgery, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Department for Clinical Genetics, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)
10 Karolinska Institutet, and Center for Psychiatry Research, Center of Neurodevelopmental Disorders (KIND), Division of Neuropsychiatry, Department of Women’s and Children’s Health, Region Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska Institutet, Department of Molecular Medicine and Surgery, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
11 Karolinska Institutet, Department of Neuroradiology, Karolinska University Hospital and Department of Clinical Neuroscience, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
12 Karolinska Institutet, and Center for Psychiatry Research, Center of Neurodevelopmental Disorders (KIND), Division of Neuropsychiatry, Department of Women’s and Children’s Health, Region Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Stockholm County Council, Child and Adolescent Psychiatry, Stockholm Health Care Services, Stockholm, Sweden (GRID:grid.425979.4) (ISNI:0000 0001 2326 2191); Social Work and Speech Pathology, Curtin University, Curtin Autism Research Group, School of Occupational Therapy, Perth, Australia (GRID:grid.1032.0) (ISNI:0000 0004 0375 4078)